Tag: CTIC

ICLD, PGCX, FREE & Extended Watchlist

InterCloud Systems, Inc. ICLD

–
ICLD appeared in Friday morning’s extended watchlist, and by the time we sent out an afternoon update, had already impressed with a 97% gain from 4.41 to 8.67. The stock’s continued momentum would carry it even further, reaching a daily high of 10.35, a total possible gain of 135% off of the morning low. All that on nearly 58X the 3mo. average volume.

It appears as if further gains will be added to that figure today, with the stock gapping up into the 13.00-range this morning.

The catalyst for this monstrous move from ICLD appears to be extremely improved 3rd quarter figures over the same period last year. Announced on Thursday, highlights include a revenue increase of nearly 450% and gross profits nearly 5x that of the previous year. >>> Read 3rd Quarter Results

Virtual Sourcing, Inc. PGCX

PGCX, a stock that provided us with an intraday gain of 26% on Friday, bouncing to a high of .1225, closed one tick under that mark at .1224. We still have our eye PGCX today as the company has announced the completion of an important step along the way to a planned exchange uplisting. The full press release is included below:

WASHINGTON, DC, Nov 18, 2013 (Marketwired via COMTEX) — Virtual Sourcing, Inc. (OTC Pink: PGCX) has received an increase to $25 million in acquisition financing in preparation for additional acquisitions currently being reviewed. Our capital formation agreement for acquisitions and operational funding remains at $25 million bringing our current total engagement package to $50,000,000.

We are expecting to close the initial acquisition in mid-December. Our auditors are continuing to work diligently with the expectation of releasing the audit report near the end of the first week of December 2013 allowing us to close the transaction shortly thereafter.

Discussions have been held on the need to increase the capital formation package. These discussions indicate that it is likely the capital formation engagement would be increased to at least sufficient funds to complete the second acquisition in Spring 2014. The requirement to close the second acquisition would cause the capital formation package to rise to approximately $75 million meeting our total funding needs of $100,000,000 to complete both acquisitions plus supply funding for product expansion and operations.

We are developing an initiative to reach institutional investors and the brokerage community. The initiative will have a full launch in January 2014 with site visits to several locations. This project is the next primary step to raising our share prices to the sustainable level required to meet the qualifications for acceptance to the AMEX/NYSE stock exchange.

FreeSeas, Inc. FREE

Beginning on September 10th, FREE began a monumental 320% run for us, going from a low of .2213 all the way up to .9287. In the weeks that have followed the stock has been searching out support, finally finding its bottom just below .30.

On Friday, the stock closed near the high of day, and this morning we are seeing a slight gap-up, so we now have FREE on rebound-watch. Regaining even a fraction of September highs would mean significant gains from current levels.

Extended Watchlist:
BSPM,CTIC, CPRX, OTIV, OXBT, SNTA, FNMA, FMCC

PLUG, YRCW, VNDA, PCGX, FNMA, FMCC & Extended Watchlist

Plug Power, Inc. PLUG
–
PLUG continues to be a winner for us, seemingly, every time we mention it in one of our reports. Yesterday, we were anticipating a potentially profitable session based on observed indicators on the chart, and once again our timing proved to be extremely accurate.After touching a low of .58 early in the day, PLUG would climb for the rest of the session, closing at its high-of-day, .67. That represents a solid 16% increase on slightly less than twice the 3mo. average volume. With a head of steam like that building, we’ll be sure to continue monitoring PLUG today.

YRC Worldwide, Inc. YRCW

On Wednesday, YRCW appeared in our extended watchlist as a play that was gapping down, noting that we were on the lookout for a reversal. That’s just what happened, as we observed a 13% intraday move from the stock on that day. We continued to monitor YRCW yesterday and were once again met with positive results.

Trading in a daily range from a low of 7.51, YRCW was up as high as 8.699, marking a 16% intraday gain.

Vanda Pharmaceuticals, Inc. VNDA

After an appearance in Tuesday’s extended watchlist, and a feature in Wednesday’s report, wherein we were expecting FDA-related news from VNDA regarding a New Drug Application. The result was so highly-anticipated that it warranted NASDAQ to halt the stock on Thursday.

The FDA committee indeed met and are recommending approval of the company’s drug “tasimelteon, proposed tradename HETLIOZ(TM), for the treatment of Non-24-Hour Disorder (Non-24) in the totally blind.” Non-24 is

As expected, the stock has resumed trading today and is gapping up this morning, with trades going off in the 14.60-16.50 range. This is already a substantial increase from our initial alert price at 11.07, and with positively-charged FDA news hot off the presses, profit margins could very well expand even further.

Virtual Sourcing, Inc. PGCX

Our timing was just a little bit early in our October 24th mention of PGCX. We were looking out for a bottom that would take until early last week to occur. However, when it did, it bounced off of support at .08, and subsequently made a 100% rip to .16.

The stock caught our eye yesterday, as it appeared to be searching out support once again, and found it at .09. We are curious to see how high the resulting bounce here could be in comparison to the one we observed previously.

Fannie Mae FNMA
& Freddie Mac FMCC

We follow this mortgage lending pair fairly regularly, and began re-introducing them onto our main watchlist on October 24th. At the time FNMA was trading as low as 1.86, and FMCC at 1.69.  Each has been on a steady increase since that time, with Fannie hitting a high of 3.08, and Freddie, 2.90. Both show no signs of relenting today, and are gapping up in premarket trading. (FNMA last traded at 3.42, FMCC at 3.30)

Some of you might remember the gains amounting to 350% we saw from these play earlier this year, so if past results are any indication of what we can expect from these two moving forward, we could be in for yet another wild ride at their expense.

Extended Watchlist:
CTIC, ICLD, FENG, SKBI, FONR, NOK, QCOM

ATOS, CTIC, APP & Extended Watchlists

Atossa Genetics, Inc.  ATOS
–
We tacked ATOS onto our extended watchlist yesterday morning, noting that the stock was in the midst of a “Huge gap down” and that we were “watching for a potential bounce”. Indeed that was the case, as the stock touched a low of 2.54 before a reversal carried it as high 3.18, a 25% intraday gain. As usual, when we see big gap-downs, we are looking out for quick-strike opportunities that allow us to make a rapid profit and a timely exit.We have uncovered a few other stocks fitting that profile that we will be monitoring for similar activity today:

Tower Group Intl. Ltd. TWGP

CEL-SCI Corp. CVM

Celgene Corp. CELGZ

Cell Therapeutics, Inc. CTIC
Another play from yesterday’s extended watchlist, CTIC opened at its low of day, and rumbled upward for a 23% move, closing at the high of day on nearly 12X its 3mo. average volume. In doing so, it managed to break a previous swing high at 1.80, a level we’d like to see hold as support moving forward.

We prepared the the following video chart on CTIC:

With the kind of momentum CTIC built up over the course of the day yesterday, this is one play that will be near the top of our watchlists in the near future. The catalyst here seems to be an agreement announced yesterday between the company and the FDA as outlined in the press release below.

SEATTLE, Oct. 7, 2013 /PRNewswire via COMTEX/ — Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the company reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the planned pivotal Phase 3 clinical trial, known as the PERSIST-2 trial, evaluating pacritinib compared to best available therapy, including approved JAK2 inhibitors such as ruxolitinib, in patients with myelofibrosis whose platelet counts are <100,000/uL. The SPA is a written agreement between CTI and the FDA regarding the design, endpoints and planned statistical analysis approach of the trial to be used in support of a potential New Drug Application (NDA) submission. The PERSIST-2 trial is the second of two planned Phase 3 clinical trials in patients with myelofibrosis. CTI expects to initiate the PERSIST-2 clinical trial in the fourth quarter of 2013. >>> FULL STORY

American Apparel, Inc. APP

APP is another stock we have tracked for an extended period of time. We have been watching this one to sniff out a bottom for the past few months, and wanted to re-enter it into the conversation today, as that point may be drawing near. A quick peek at the chart below clearly shows just that:

Extended Watchlist:

JCP, AGEN, CBMX, NAVB, TKMR